住院患者新型口服抗凝药物相关问题调查与分析
Investigation and analysis on drug-related problems of new oral anticoagulants in hospitalized patients
杨翠 1宋奇修1
作者信息
- 1. 安徽医科大学第一附属医院/安徽省公共卫生临床中心药学部,安徽合肥 230012
- 折叠
摘要
目的 探讨住院患者新型口服抗凝药物(NOACs)的使用情况和临床应用药物相关问题(DRPs),为促进NOACs的合理使用提供参考.方法 收集安徽医科大学第一附属医院2021年10月至2022年9月使用NOACs的住院患者病历共586份,依据相关指南、法规等对其进行回顾性点评,参考符合中国人群和医疗模式的《中国药物相关问题分类系统(V1.0)》使用标准对所发现的DRPs汇总分析.结果 586份住院病历中,女性居多(52.4％),年龄为(69.5±12.6)岁,使用NOACs最常见的病因是非瓣膜性心房颤动(272例,46.4％),涉及3个品种、8个品规;其中358例患者发生了DRPs,累计发生389个DRPs,包括213个(54.8％)DRP1.1、72个(18.5％)DRP2.1、4 个(1.0％)DRP3.1、65 个(16.7％)DRP3.2 和 35 个(9.0％)DRP3.3.结论 本院 NOACs 的使用问题主要表现为单次剂量过低、给药频次过少及无指征用药.
Abstract
AIM To investigate the use of new oral anticoagulants(NOACs)and clinically relevant drug-related problems(DRPs)in hospitalized patients,in order to provide a reference for promoting the rational use of NOACs.METHODS A total of 586 medical records of inpatients using NOACs at the First Affiliated Hospital of Anhui Medical University from October 2021 to September 2022 were collected.Retrospective reviews were conducted according to relevant guidelines and regulations.The summary analysis of the observed DRPs was performed with reference to the criteria used in the Chinese Classification System for Drug-Related Problems(V1.0),which is adapted to the Chinese population and healthcare model.RESULTS Among the 586 cases,the majority were females(52.4％),and the average age was(69.5±12.6)years old.The most common indication for the use of NOACs was nonvalvular atrial fibrillation(272 cases,46.4％),which involved three varieties and eight criteria.DRPs occurred in 358 patients,with a total of 389 DRPs identified,including 213(54.8％)DRP1.1,72(18.5％)DRP2.1,4(1.0％)DRP3.1,65(16.7％)DRP3.2,and 35(9.0％)DRP3.3.CONCLUSION The use of NOACs in our hospital are mainly manifested as low single doses,infrequent administration,and lack of indication for medication.
关键词
新型口服抗凝药物/药物相关问题/心房颤动/用药审查/安全Key words
new oral anticoagulants/drug-related problems/atrial fibrillation/medication review/safety引用本文复制引用
出版年
2024
NETL
NSTL
万方数据